 complex femoropopliteal artery lesions: the
randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superﬁcial femoral artery occlusive disease).
J Am Coll Cardiol 2013;62:1320-7.
214. Johnston PC, Vartanian SM, Runge SJ, Hiramoto JS, Eichler CM,
Owens CD, et al. Risk factors for clinical failure after stent graft
treatment for femoropopliteal occlusive disease. J Vasc Surg 2012;56:
998-1006. 1007 e1; discussion 1006-7.
215. Gorgani F, Telis A, Narakathu N, LaBarbera M, Babaev A. Longterm outcomes of the Viabahn stent in the treatment of in-stent
restenosis in the superﬁcial femoral artery. J Invasive Cardiol
2013;25:670-4.
216. Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A,
et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superﬁcial femoral and/or
popliteal peripheral artery disease: 12-month results from the IN.
PACT SFA randomized trial [published online ahead of print
December 3, 2014]. Circulation pii: CIRCULATIONAHA.114.
011004.
217. Joels CS, York JW, Kalbaugh CA, Cull DL, Langan EM. Surgical
implications of early failed endovascular intervention of the superﬁcial
femoral artery. J Vasc Surg 2008;47:562-5.
218. Bradbury AW, Adam DJ, Bell J, Forbes JF, Fowkes FG, Gillespie I,
et al. Bypass versus Angioplasty in Severe Ischaemia of the Leg
(BASIL) trial: an intention-to-treat analysis of amputation-free